Retatrutide Dosage

Retatrutide is a synthetic peptide that acts on multiple receptors simultaneously, achieving beneficial effects. This peptide acts through the Glucagon-like peptide-1 receptor (GLP-1), the glucose-dependent insulinotropic polypeptide receptor (GIP), and the glucagon receptor. Due to this property, it is better known in the literature as Triple G.

Since it acts through three receptors, it achieves various effects; increased insulin secretion, slowed gastric emptying, stimulation of lipolysis, accelerated metabolism, and increased energy expenditure. In addition, by directly acting on the central nervous system, the peptide also achieves effects such as reducing appetite and increasing the feeling of satiety.

Because of this triple effect, Retatrutide is considered to have great potential in the treatment of type 2 diabetes mellitus, insulin resistance, and various forms of obesity. Scientists believe that this peptide can reduce the severity of inflammation, which means that it is not contraindicated in patients with inflammatory diseases.

Dosage Chart

About the Peptide

Retatrutide is a synthetic peptide, designed to act on three receptors, thereby achieving many beneficial effects simultaneously.

Acting on the Glucagon-like peptide-1 receptor (GLP-1), the peptide achieves effects such as stimulating insulin production and suppressing gastric emptying. On the other hand, it binds to the glucose-dependent insulinotropic polypeptide receptor (GIP), leading to a reduction in appetite and an increase in insulin receptor sensitivity. Ultimately, through the glucagon receptor, there is an increase in energy expenditure and stimulation of lipolysis (the process of fat breakdown).

Obesity is one of the most common metabolic diseases in men and women, and the reasons for its occurrence vary. Causative factors for its occurrence can be medical (hormonal disorders, side effects of medications, or thyroid diseases) and modifiable lifestyle factors (lack of physical activity, excessive calorie intake, or lack of sleep).

Therapy always requires a multi-agency approach that is reflected in lifestyle and habits. Still, medications can certainly be part of the treatment, helping to speed up the weight loss process and bring it under control.

The peptide primarily binds to receptors in the liver, stimulating lipolysis. It then binds to receptors in the brain (mainly the hypothalamus), acting to achieve a prolonged feeling of satiety. Patients eat smaller amounts of food without feeling hungry, leading to weight loss.

Type 2 diabetes is a common metabolic disease that is usually preceded by insulin resistance. It is a condition characterized by reduced sensitivity of insulin receptors, resulting in a large amount of glucose being released into the blood. Therapies that were previously used had a dangerous side effect in the form of hypoglycemia.

This occurred as a result of excessively low glucagon and too much insulin, which resulted in a sudden drop in blood sugar. Retatrutide does not cause this side effect because it lowers glucagon (a hormone that raises glucose levels) only when necessary. This property makes the peptide much safer to use.

Scientific studies have confirmed that this peptide, through its metabolism, can lead to increased receptor sensitivity and reduced blood sugar levels. Patients in clinical studies have generally reported improved conditions and improved glycemic control.

List of Uses

For Treating Different Forms of Obesity

Obesity is one of the most common metabolic diseases of modern times. It is characterized by a high percentage of fat deposits and excess weight, which, depending on the type of obesity, is deposited in some areas of the body. This disease is increasingly affecting children and the younger population, and the reasons for its occurrence vary. Sometimes the disease can occur as a result of a medical problem, including hormonal imbalance, hypothyroidism, or an adverse effect of therapy (antidepressants). On the other hand, the reasons for its occurrence are often psychological, such as when patients have a sedentary lifestyle, lack of physical activity, emotional overeating, and others.

Therapy requires a multidisciplinary approach and is primarily reflected in a lifestyle change. Patients are advised to increase their physical activity, adopt a healthy diet, get sufficient sleep, and increase their fluid intake. If this approach does not yield results or progress is slow (in severe cases), medication may be used. The great advantage of Retatrutide compared to previous beneficial therapies is that it does not lead to hormonal imbalances or hypoglycemia, which protects patients from unwanted effects.

According to scientific studies and research, it has been determined that Retatrutide can be used to treat obesity, regardless of its cause. The mechanism of action occurs through three receptors, the most important of which are the GLP-1 receptors. By binding to receptors located in the central nervous system, they act on the parts specifically responsible for perceiving feelings of hunger and satiety (arcuate nucleus), thus producing a feeling of satiety and reducing the feeling of hunger. Additionally, the peptide can slow down gastric emptying, thereby creating a prolonged sense of satiety, which helps patients feel fuller for a longer period.

Through the GIP receptor, the peptide achieves effects such as strengthening muscle mass, which can significantly help in the weight loss process (for this effect, increased physical activity is also required). Through the Glucagon receptor, Retatrutide acts by stimulating lipolysis (the process of breaking down small deposits) in the liver and accelerating basal metabolism. Through these effects, the peptide effectively leads to a decrease in body weight. All patients included in the clinical study reported weight loss, significant weight changes, and with it an improvement in general health and satisfaction with their physical appearance.

As a Part of the Therapy for Diabetes Mellitus Type 2

Diabetes Mellitus type 2 is a metabolic disease that increasingly affects young people. This disease is most often preceded by insulin resistance. This is a condition in which the receptors on the cell surface are insensitive to insulin, or there are not enough of them. This means that insulin cannot bind and perform its primary role, which is to facilitate the uptake of glucose from food into cells, allowing it to later be converted into valuable energy for the entire body. This means that glucose remains free in the blood, and the sugar level rises. Regardless of food intake, the patient remains hungry because none of the calories have been converted into energy. Therefore, the patient consumes additional amounts that are stored as subcutaneous fat.

Therapies used up to now have been relatively effective but dangerous, as they often lead to hypoglycemia. This is an unsafe condition that occurs when insulin levels are too high and glucagon levels are too low. Blood sugar level drops sharply, and symptoms such as tremors, sweating, paleness, and fainting occur. Sometimes it can even lead to hypoglycemic coma and death. That is why Retatrutide does not lead to hypoglycemia because its mechanism of action is related to the blockade of glucagon secretion only when necessary (rarely).
The peptide, acting through the GLP-1 receptor in the pancreas, stimulates the secretion of insulin from the beta cells of the pancreas, thereby contributing to the reduction of glycemia. In addition, these receptors also regulate the metabolism of glucagon (a hormone that raises the level of glucose in the body).

Through the GIP receptor, the peptide also stimulates insulin secretion, depending on food intake. The effect that the peptide creates via the Glucagon receptor is somewhat different. It stimulates the processes of gluconeogenesis, but without a sudden spike in glucose. It is this type of receptor that is responsible for the absence of hypoglycemia as an unwanted effect, which separates this peptide from previous therapy.

Dosage Calculator

Dosage, as always, depends on the indication and differs in the case of treating obesity and type 2 diabetes. In the treatment of obesity, therapy begins with 1 mg of peptide, which is administered subcutaneously once a week. This window of treatment lasts one to two weeks and does not have a potent therapeutic effect, rather, it helps the patient's body adjust to the therapy. Over the next five to ten weeks, the optimal dose is 4 mg, administered once weekly. This is when the first signs of decreased appetite and weight loss appear. Over the next eight to twelve weeks, the dose is 8mg, and visible results are achieved. After the thirteenth week, the maintenance phase and the optimal dose of 12mg are reached. The recommended dose should never be exceeded or adjusted independently of the prescribed regimen.

Conclusion

Retatrutide is a synthetic peptide that acts on the GLP-1, GIP, and Glucagon receptors. In this way, it achieves numerous beneficial effects, the most prominent of which are weight loss and reduced blood sugar levels. If used in optimal doses, they can be potent in treating Obesity and Type 2 Diabetes Mellitus. Regardless of the results achieved, Retatrutide will remain a subject of future research.